TABLE 1.
Demographic, clinical and biochemical characteristics of renal transplant recipients (RTR) stratified by antibody response.
| Variable | Total cohort (N = 99) | Negative (N = 14) | Positive (N = 85) | p value |
|---|---|---|---|---|
| RTR characteristics | ||||
| Age, years, [median (IQR)] | 66 (53–73) | 71.5 (68–74) | 63 (52–72) | 0.008 b |
| Female sex, n (%) | 25 (25.3) | 4 (28.6) | 21 (24.7) | 0.76 |
| Transplant to 3rd vaccine, years [median (IQR)] | 3.4 (1.4–9.2) | 2.8 (1.0–6.2) | 3.6 (1.4–10.0) | 0.25 |
| 2nd to 3rd vaccine, days [median (IQR)] | 175 (171–178) | 177.5 (174–178) | 175 (170–178) | 0.34 |
| 3rd vaccine to antibody testing, days [median (IQR)] | 21 (21–21) | 21 (21–33) | 21 (21–21) | 0.28 |
| ESRD etiology, n (%) | ||||
| APCKD | 14 (14.1) | 0 (0) | 14 (16.5) | 0.15 |
| Diabetic nephropathy | 20 (20.2) | 6 (42.9) | 14 (16.5) | |
| Glomerulonephritis | 28 (28.3) | 3 (21.4) | 25 (29.4) | |
| Nephrosclerosis | 14 (14.1) | 2 (14.3) | 12 (14.1) | |
| Other | 16 (16.2) | 3 (21.4) | 13 (15.3) | |
| Unknown | 7 (0.1) | 0 (0) | 7 (8.2) | |
| ESRD secondary to DN | 20 (20.2) | 6 (42.9) | 14 (16.5) | 0.02 a |
| Time on dialysis, years [median (IQR)] | 0.6 (0–1.5) | 0.6 (0–3.0) | 0.6 (0–1.5) | 0.99 |
| Transplant number, n (%) | ||||
| 1 | 92 (92.9) | 13 (92.9) | 79 (92.9) | 0.64 |
| 2 | 4 (4) | 1 (7.1) | 3 (3.5) | |
| 3 | 3 (3) | 0 (0) | 3 (3.5) | |
| Donor type, n (%) | ||||
| Living | 81 (81.8) | 12 (85.7) | 69 (81.2) | 0.82 |
| Deceased | 16 (16.2) | 2 (14.3) | 14 (16.5) | |
| Unknown | 2 (2) | 0 (0) | 2 (2.4) | |
| Medical history | ||||
| Hypertension | 74 (74.7) | 10 (71.4) | 64 (74.1) | 0.83 |
| SBP 3-months average [median (IQR)] | 131.8 (120.0–141.5) | 139.5 (117.5–153.5) | 131 (120.0–140.9) | 0.25 |
| DBP 3-months average [median (IQR)] | 73.5 (68.0–79.5) | 73 (66.8–79.5) | 73.5 (68.0–79.5) | 0.61 |
| Ischemic heart disease | 10 (10.1) | 1 (7.1) | 9 (10.6) | 0.69 |
| Congestive heart failure | 10 (10.1) | 2 (14.3) | 8 (9.4) | 0.58 |
| Diabetes | 37 (37.4) | 7 (50) | 30 (35.3) | 0.29 |
| HbA1C 6-months average (%) [median (IQR)] | 6.4 (5.7–7.1) | 6.4 (5.8–7.6) | 6.4 (5.7–6.9) | 0.59 |
| Weight, (kg) [median (IQR)] | 80 (70–92) | 82.1 (70–89) | 79.1 (70–92.2) | 0.79 |
| BMI, kg/m2 [median (IQR)] | 26.9 (23.2–31.1) | 26.6 (23.2–31.8) | 27 (23.6–30.9) | 0.91 |
| Average Laboratory results 1 month before antibody testing day [median (IQR)] | ||||
| White blood cell (K/μL) | 7.3 (6.1–8.9) | 7.1 (6.4–8.1) | 7.4 (6.0–9.0) | 0.73 |
| Lymphocyte absolute (K/μL) | 1.7 (1.3–2.1) | 1.6 (1.2–1.7) | 1.7 (1.4–2.2) | 0.18 |
| Neutrophils absolute (K/μL) | 4.6 (3.6–5.7) | 4.3 (3.9–5.2) | 4.8 (3.6–5.7) | 0.99 |
| Neutrophil/lymphocyte ratio | 2.7 (2.0–3.5) | 2.9 (2.6–3.2) | 2.7 (2.0–3.6) | 0.48 |
| Hemoglobin (g/dl) | 13.2 (12.2–14.0) | 12.7 (11.8–13.4) | 13.2 (12.3–14.0) | 0.36 |
| Platelets (K/μL) | 179 (149–223.5) | 175 (168–196) | 182 (147.5–225.3) | 0.91 |
| Creatinine (mg/dl) | 1.1 (0.9–1.4) | 1.4 (1.2–1.7) | 1.1 (0.9–1.3) | 0.03 a |
| eGFR (CKD-EPI)** | 64.7 (51.3–82.7) | 46.6 (37.4–53.7) | 67.9 (54.0–83.6) | 0.008 b |
| Glucose (mg/dl) | 115.5 (101–145.2) | 129 (123–170) | 113 (100.9–141) | 0.057 |
| Albumin (g/dl) | 4.1 (3.8–4.2) | 4 (3.7–4.1) | 4.1 (3.9–4.2) | 0.36 |
| Globulins (g/dl) | 2.6 (2.4–2.9) | 2.5 (2.3–2.7) | 2.7 (2.4–2.9) | 0.08 |
| C-reactive protein (mg/L) | 3.26 (1.17–8.79) | 2.7 (1.52–6.72) | 3.29 (1.08–8.88) | 0.66 |
Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; ESRD, end stage renal disease, SBP, systolic blood pressure.
a
<0.05.
b
<0.01.
**
eGFR, was calculated according to the following CKD-EPI, formula: eGFR, 141* min (Scr/k, 1)α * max (Scr/k, 1)-1.209 * 0.993Age * 1.018 * 1.159 (if black) (where Scr - standardized serum creatinine; k = 0.7 if female, 0.9 if male; α = −0.329 if female, −0.411 if male; min = the minimum of Scr/k of 1; max = the maximum of Scr/k or 1).
When p value is significant, below 0.05 or below 0.01 the values are bolded.